Brand & Product Security

The collaboration is centered around meeting track-and-trace requirements.

In the final part of her interview with Pharma Commerce Editor Nicholas Saraceno, Ilisa B.G. Bernstein, President of Bernstein Rx Solutions, LLC, comments on industry’s preparedness for DSCSA compliance and provides an update as to where pharma is in terms of RFID label adoption.

In the second part of her interview with Pharma Commerce Editor Nicholas Saraceno, Ilisa B.G. Bernstein, President of Bernstein Rx Solutions, LLC, discusses the best practices that compliance teams should consider as the end of the stabilization period approaches this November.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Ilisa B.G. Bernstein, President of Bernstein Rx Solutions, LLC, highlights the hard-hitting points that she anticipated will be covered during her session at the 2024 HDA Traceability Seminar.

How can industry stakeholders ensure the quality and supply chain security of existing product?

Panel offers suggestions on how compliance teams should be considering handling SOPs, stabilization, and much more.

Session uncovers distributors’ experiences with the Waiver, Exception, or Exemption request process, and how these affect the overall supply chain.

The agency provides an update surrounding the Act’s implementation efforts.

In the final part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, comments on other ways to limit ‘bad actors’ attempts to sneak counterfeit drugs into the supply chain, aside from the DSCSA.

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, predicts the likelihood of stabilization period postponement.

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, describes the outcome of the joint public meeting held by the Partnership for DSCSA Governance and the FDA.

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, discusses the state of affairs surrounding the Drug Supply Chain Security Act, along with opportunities for improvement.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, offers a brief overview of the Drug Supply Chain Security Act.

The agreement revolves around providing and maintaining supply chain transparency.

Webinar dives into the trends, technology, and market necessities that can help tackle these obstacles.

These advancements continue to act as a key driver in helping to boost the security, efficiency, and innovation of global industries, include pharma.

Radio frequency identification (RFID) not only helps hospitals boost their medication safety standards, it also allows clinicians to continue to provide quality patient care.

The offering reportedly helps avoid product quarantine.

OneScan 7.1 is expected to boost compliance, while also improving pharma supply chain efficiencies.

A look at the challenges that need to be addressed during the FDA stabilization period.

The predicted value is largely driven by manufacturers' prioritization of brand protection.

EdenHelp is expected to provide HCPs and patients with real-time access to Rx drug and medical device information.

JAMA Health Forum details the DSCSA and stresses the value of protecting the pharmaceutical supply chain from adulterated products.

This year’s PC Podcast episodes ranged in topic, from DSCSA compliance to pharmacovigilance.

Cloud-based service to address verification of saleable returns under the latest DSCSA regulations.

The seminar examines where members of the pharma supply chain stand in terms of preparation, being that the act has officially been enacted.

Back in Boston, Pharma Commerce tackles all things logistics at LogiPharma USA.

With new mandates right around the corner, there is an unwavering demand for pharma operations to perform at peak efficiency.

Value is attributed to the rise in counterfeit cases and ongoing regulations surrounding anti-counterfeit packaging.

A breakdown on the decision, and how to navigate these obstacles using a network approach.